Advertisement

Irish Journal of Medical Science (1971 -)

, Volume 188, Issue 1, pp 101–108 | Cite as

Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group

  • Rebabonye B. PharithiEmail author
  • Deepti Ranganathan
  • Jim O’Brien
  • Emmanuel E. Egom
  • Cathie Burke
  • Daniel Ryan
  • Christine McAuliffe
  • Marguerite Vaughan
  • Tara Coughlan
  • Edwina Morrissey
  • John McHugh
  • David Moore
  • Ronan CollinsEmail author
Original Article

Abstract

Background

Non-vitamin K antagonist oral anticoagulants (NOACs) are a major advance for stroke prevention in atrial fibrillation (AF). Use of the vitamin K antagonist (VKA), warfarin, has dropped 40% since 2010 in our institution. There is limited Irish hospital data on NOAC prescribing for stroke prevention.

Method

Single centre, retrospective observational cohort study of consecutive AF patients at increased risk of stroke and/or awaiting electrical cardioversion. Data on prescribed NOACs from February 2010 till July 2015 was collected from the electronic inpatient record. Appropriateness of prescriptions was based on CHA2DS2–VASC score and accuracy on individual NOAC SPCs. Potential drug interactions and bleeding risk were also quantified.

Results

A total of 348 patients AF and increased risk of stroke (CHA2DS2–VASC score > 1 for men and > 2 for women) were studied. Forty-eight percent were female with a mean age 71 ± 18.6 years, 52% of whom were > 75. Mean CHA2DS2-Vasc and HAS-BLED scores were 4.1 ± 1.8 and 1.4 ± 0.8, respectively. Rivaroxaban, dabigatran and apixaban were prescribed to 154 (54.2%), 106 (34.3%) and 41 (13.2%) patients, respectively. 20.4% had inaccurate prescriptions; 92.9% (n = 65) underdosed and 7.1% (n = 5) on inappropriately higher doses. Neither choice of NOAC, age, history of anaemia, previous bleeding or co-prescribed antiplatelets influenced the accuracy of prescription (p = NS), but decreased renal function appeared to do so (p = 0.05).

Conclusion

Our study highlights significant inaccuracies in NOAC prescribing. Patients commenced on NOACs should be assessed and followed up in a multidisciplinary AF clinic to ensure safe and effective prescribing and stroke prevention.

Keywords

Anticoagulation Atrial fibrillation NOAC Non-vitamin K oral anticoagulants Prescription errors 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Ronan Collins has spoken at educational meetings sponsored by Bayer, Boehringer Ingelheim, Daichii-Sankyo and Pfizer, the manufacturers of non-vitamin k oral anticoagulants,

Ethical approval

Collection of data was approved by the chairman of the SJH/AMNCH Joint Research and Ethics Committee on behalf of the regional Research and Ethics Committee.

References

  1. 1.
    Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Bauersachs R, Breithardt G (2013) Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 15(4):486–493CrossRefGoogle Scholar
  2. 2.
    European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31(19):2369–2429CrossRefGoogle Scholar
  3. 3.
    Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G (2009) The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 11(4):423–434.  https://doi.org/10.1093/europace/eun369 CrossRefGoogle Scholar
  4. 4.
    Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt G, Berger K, Ringelstein EB, Kirchhof P, Wersching H (2008) Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 29(17):2125–2132CrossRefGoogle Scholar
  5. 5.
    Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KHLG, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G (2007) Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803–2817CrossRefGoogle Scholar
  6. 6.
    Stewart S, Hart CL, Hole DJ, McMurray JJ (2002) A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113(5):359–364CrossRefGoogle Scholar
  7. 7.
    Thrall G, Lane D, Carroll D, Lip GY (2006) Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 119(448):e1–e19Google Scholar
  8. 8.
    Rabah A, Wazni O (2014) Atrial fibrillation in heart failure: catheter and surgical interventional therapies. Heart Fail Rev 19(3):325–330CrossRefGoogle Scholar
  9. 9.
    Bardai A, Blom MT, van Hoeijen DA, van Deutekom HW, Brouwer HJ, Tan HL (2014) Atrial fibrillation is an independent risk factor for ventricular fibrillation: a large-scale population-based case-control study. Circ Arrhythm Electrophysiol 7(6):1033–1039CrossRefGoogle Scholar
  10. 10.
    Brainin M, Bornstein N, Boysen G, Demarin V (2000) Acute neurological stroke care in Europe: results of the European stroke Care Inventory. Eur J Neurol 7(1):5–10CrossRefGoogle Scholar
  11. 11.
    Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36(6):1115–1119.  https://doi.org/10.1161/01.STR.0000166053.83476.4a CrossRefGoogle Scholar
  12. 12.
    Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095–1106.  https://doi.org/10.1001/archinte.165.10.1095 CrossRefGoogle Scholar
  13. 13.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151.  https://doi.org/10.1056/NEJMoa0905561 CrossRefGoogle Scholar
  14. 14.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891.  https://doi.org/10.1056/NEJMoa1009638 CrossRefGoogle Scholar
  15. 15.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992.  https://doi.org/10.1056/NEJMoa1107039 CrossRefGoogle Scholar
  16. 16.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104.  https://doi.org/10.1056/NEJMoa1310907 CrossRefGoogle Scholar
  17. 17.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur J Cardiothorac Surg 50:e1–e88.  https://doi.org/10.1093/ejcts/ezw313 CrossRefGoogle Scholar
  18. 18.
    Tellor KB, Patel S, Armbruster AL, Daly MW (2015) Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther 40(4):447–451.  https://doi.org/10.1111/jcpt.12288 CrossRefGoogle Scholar
  19. 19.
    Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW (2014) Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits 7(7):376–384Google Scholar
  20. 20.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467–1507.  https://doi.org/10.1093/europace/euv309 CrossRefGoogle Scholar
  21. 21.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093–1100.  https://doi.org/10.1378/chest.10-0134 CrossRefGoogle Scholar
  22. 22.
  23. 23.
  24. 24.
  25. 25.
    Levey AS, De Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt K-U (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80(1):17–28CrossRefGoogle Scholar
  26. 26.
    Larock AS, Mullier F, Sennesael AL, Douxfils J, Devalet B, Chatelain C, Dogne JM, Spinewine A (2014) Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother 48(10):1258–1268.  https://doi.org/10.1177/1060028014540868 CrossRefGoogle Scholar
  27. 27.
    Ruiz Ortiz M, Muniz J, Rana Miguez P, Roldan I, Marin F, Esteve-Pastor MA, Cequier A, Martinez-Selles M, Bertomeu V, Anguita M (2017) Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace.  https://doi.org/10.1093/europace/eux316
  28. 28.
    Wiggins BS, Northup A, Johnson D, Senfield J (2016) Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. Pharmacotherapy 36(2):e5–e7.  https://doi.org/10.1002/phar.1698 CrossRefGoogle Scholar
  29. 29.
    Stollberger C, Finsterer J (2017) Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy. Neurol Neurochir Pol 51(2):194–196.  https://doi.org/10.1016/j.pjnns.2017.01.010 Google Scholar
  30. 30.
    Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA, Blaauw Y, Tieleman RG (2012) Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 33(21):2692–2699.  https://doi.org/10.1093/eurheartj/ehs071 CrossRefGoogle Scholar
  31. 31.
    Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H (2013) Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace 15(8):1128–1135.  https://doi.org/10.1093/europace/eut055 CrossRefGoogle Scholar
  32. 32.
    Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H, Kettis-Lindblad A, Melhus H, Morlin C (2009) A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med 169(9):894–900.  https://doi.org/10.1001/archinternmed.2009.71 CrossRefGoogle Scholar
  33. 33.
    Morrissey E, Pharithi R, Collins R, McManamly C, Burke C, Moore D (2016) The role and impact of a pharmacist in a multi-disciplinary a trial fibrillation clinic. BMJ Publishing Group Ltd and British Cardiovascular SocietyGoogle Scholar
  34. 34.
    Grimes TC, Deasy E, Allen A, O'byrne J, Delaney T, Barragry J, Breslin N, Moloney E, Wall C (2014) Collaborative pharmaceutical care in an Irish hospital: uncontrolled before-after study. BMJ Qual Saf 23:574–583CrossRefGoogle Scholar
  35. 35.
    Martin K, Beyer-Westendorf J, Davidson B, Huisman M, Sandset P, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14(6):1308–1313CrossRefGoogle Scholar
  36. 36.
    Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, De Backer G, Roffi M, Aboyans V, Bachl N, Bueno H, Carerj S, Cho L, Cox J, De Sutter J, Egidi G, Fisher M, Fitzsimons D, Franco OH, Guenoun M, Jennings C, Jug B, Kirchhof P, Kotseva K, Lip GY, Mach F, Mancia G, Bermudo FM, Mezzani A, Niessner A, Ponikowski P, Rauch B, Ryden L, Stauder A, Turc G, Wiklund O, Windecker S, Zamorano JL (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 23(11):Np1–np96.  https://doi.org/10.1177/2047487316653709 CrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2018

Authors and Affiliations

  • Rebabonye B. Pharithi
    • 1
    Email author
  • Deepti Ranganathan
    • 1
  • Jim O’Brien
    • 1
  • Emmanuel E. Egom
    • 1
  • Cathie Burke
    • 2
  • Daniel Ryan
    • 2
  • Christine McAuliffe
    • 3
  • Marguerite Vaughan
    • 3
  • Tara Coughlan
    • 2
  • Edwina Morrissey
    • 3
  • John McHugh
    • 4
  • David Moore
    • 1
  • Ronan Collins
    • 2
    Email author
  1. 1.Department of CardiologyAdelaide and Meath Hospital, Incorporated with National Children HospitalDublinIreland
  2. 2.Department of Age-Related Healthcare and Stroke ServiceAdelaide and Meath Hospital, Incorporated with National Children HospitalDublinIreland
  3. 3.Department of PharmacyAdelaide and Meath Hospital, Incorporated with National Children HospitalDublinIreland
  4. 4.Department of HaematologyAdelaide and Meath Hospital, Incorporated with National Children HospitalDublinIreland

Personalised recommendations